PlumX Metrics
Embed PlumX Metrics

Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients

Revista Alergia Mexico, ISSN: 2448-9190, Vol: 71, Issue: 4, Page: 218-228
2024
  • 0
    Citations
  • 0
    Usage
  • 0
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Article Description

Objective: to perform a cost-effectiveness analysis of asthma treatment with budesonide/formoterol against other treatment options used at Mexico’s National Institute for Respiratory Diseases. Methods: A complete economic evaluation of cost-effectiveness from a public health perspective, comparing the use of budesonide/formoterol as maintenance therapy with fluticasone/vilanterol in 103 female asthma patients managed at INER between 2015 and 2021. Results: Average cost per patient was $743.23 USD, $733.36 USD for budesonide/formoterol and $767.24 USD for fluticasone/vilanterol. Pharmacological treatment represented over 70% of management costs for both groups, followed by follow-up visits and exacerbation management costs. LABA-ICS represented the highest proportion of pharmacologic management costs with a statistically significant difference amongst groups with an incremental cost of $80.17 USD for the fluticasone/vilanterol group. The budesonide/formoterol group showed an ICER of $613.31 USD for reducing the proportion of patients experiencing exacerbations during follow-up. Considering the willingness to pay threshold based on one GDP per capita ($10,902.98 USD in 2022), budesonide/formoterol represented a very cost-effective option. Conclusions: The ICER favored budesonide/formoterol over fluticasone/vilanterol in terms of cost-effectiveness. A 5.5% reduction in patient exacerbations indicated decreased disease burden. While not statistically significant, fewer exacerbations per patient might still cut costs by lowering emergency visits and hospitalizations.

Bibliographic Details

María del Carmen Cano-Salas; José L. Miguel-Reyes; Erika C. López-Estrada; Jorge Salas-Hernández; Monserrat E. Arroyo-Rojas; Mauricio Castañeda-Valdivia; Monserrat Escobar-Preciado; Homero Garcés-Flores; Silvia Guzmán- Vázquez; Sergio R. García-García; Herman Soto-Molina

Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know